Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135525 | 0.88 | KMT2A (0.60) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL31652641 | 0.86 | KMT2A (0.75) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL12914158 | 0.86 | KMT2A (0.58) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL21332462 | 0.85 | KMT2A (0.66) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL120274 | 0.84 | KMT2A (0.61) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL12734985 | 0.83 | KMT2A (0.66) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL178687 | 0.82 | KMT2A (0.81) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29423575 | 0.82 | KMT2A (0.81) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29397906 | 0.82 | KMT2A (0.81) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL8772818 | 0.81 | KMT2A (0.58) | KMT2AEPHX2FABP5FABP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754475-B1 | Use of C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS INC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-7183260-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1754475-A1 | Use of C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | Idun Pharmaceuticals, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1091930-B1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS INC (US) | 2006-12-13 | — | — | EP | disclosed |
| US-7053056-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1351975-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6544951-B2 | Antiinflammatory agents; autoimmune diseases, nervous system degradation | IDUN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2002057298-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1091930-A1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| US-6197750-B1 | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS | IDUN PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| WO-2000001666-A1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | KMT2A 4305/4885EPHX2 2787/4885FABP5 2597/4885 |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | KMT2A 4305/4885EPHX2 2787/4885FABP5 2597/4885 |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CASP3, IAPP, DPP3 | KMT2A 4310/4885EPHX2 2532/4885FABP5 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.